New director for Mission Therapeutics
Cambridge life science company Mission Therapeutics has appointed Dr Bobby Soni to its board with immediate effect. He replaces Rob Woodman as the representative for IP Group plc.
Mission is a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases.
Dr Soni is currently director of healthcare investments at Touchstone Innovations, now part of the IP Group plc. He joined Touchstone (previously Imperial Innovations) in 2015 from Novo Seeds, the early stage investment arm of Novo AS, where he worked as investment director.
Dr Soni has 17 years’ experience in the life science industry covering drug development, business development and venture capital investment.
He is a non-executive director of STORM Therapeutics, Enterprise Therapeutics, Artios Pharma, Pulmocide, and Autifony.
• PHOTOGRAPH SHOWS: Dr Bobby Soni